中华危重症医学杂志(电子版)
中華危重癥醫學雜誌(電子版)
중화위중증의학잡지(전자판)
CHINESE JOURNAL OF CRITICAL CARE MEDICINE ( ELECTRONIC EDITON)
2011年
6期
13-15
,共3页
陈可儿%范湘芸%范小芬%邓银泉
陳可兒%範湘蕓%範小芬%鄧銀泉
진가인%범상예%범소분%산은천
脂肪肝%肥胖症%人体质量指数%胰岛素抵抗
脂肪肝%肥胖癥%人體質量指數%胰島素牴抗
지방간%비반증%인체질량지수%이도소저항
Fatty liver%Obesity%Body mass index%Insulin resistance
目的 观察非酒精性脂肪性肝病(NAFLD)患者的不同肥胖程度与胰岛素抵抗(IR)状态的相关性.方法 对符合诊断的168例NAFLD患者测定身高、体质量、空腹血糖(FPG)、及空腹胰岛素(FINS),计算体质量指数(BMI)和稳态模型IR指数(HOMA-IRI),以同期不嗜酒的32例健康人作为对照.结果 与健康对照组比较,NAFLD患者BMI、FPG、FINS、HOMA-IRI水平明显升高,差异均有统计学意义(P均<0.05).而NAFLD患者中,随着肥胖程度的增加,IR也随之逐渐加重,差异具有统计学意义(P均<0.05).结论 NAFLD患者存在着明显的高胰岛素血症和IR,肥胖可加重了患者的IR,并继发糖代谢紊乱.
目的 觀察非酒精性脂肪性肝病(NAFLD)患者的不同肥胖程度與胰島素牴抗(IR)狀態的相關性.方法 對符閤診斷的168例NAFLD患者測定身高、體質量、空腹血糖(FPG)、及空腹胰島素(FINS),計算體質量指數(BMI)和穩態模型IR指數(HOMA-IRI),以同期不嗜酒的32例健康人作為對照.結果 與健康對照組比較,NAFLD患者BMI、FPG、FINS、HOMA-IRI水平明顯升高,差異均有統計學意義(P均<0.05).而NAFLD患者中,隨著肥胖程度的增加,IR也隨之逐漸加重,差異具有統計學意義(P均<0.05).結論 NAFLD患者存在著明顯的高胰島素血癥和IR,肥胖可加重瞭患者的IR,併繼髮糖代謝紊亂.
목적 관찰비주정성지방성간병(NAFLD)환자적불동비반정도여이도소저항(IR)상태적상관성.방법 대부합진단적168례NAFLD환자측정신고、체질량、공복혈당(FPG)、급공복이도소(FINS),계산체질량지수(BMI)화은태모형IR지수(HOMA-IRI),이동기불기주적32례건강인작위대조.결과 여건강대조조비교,NAFLD환자BMI、FPG、FINS、HOMA-IRI수평명현승고,차이균유통계학의의(P균<0.05).이NAFLD환자중,수착비반정도적증가,IR야수지축점가중,차이구유통계학의의(P균<0.05).결론 NAFLD환자존재착명현적고이도소혈증화IR,비반가가중료환자적IR,병계발당대사문란.
Objective To investigate the correlation between degree of obesity and insulin resistance (IR) in patients with nonalcoholic fatty liver disease (NAFLD). Methods A total of 168 patients with NAFLD were enrolled and 32 healthy subjects were served as controls spontaneously.Body height,weight,fasting blood-glucose (FPG) and fasting insulin (FINS) were recorded and body mass index (BMI) and homeostasis model assessment of insulin resistance index (HOMAIRI) were calculated. Results Levels of BMI,FPG,FINS,HOMA-IRI in patients with NAFLD were all elevated as compared with the controls (all P < 0.05). Meanwhile, with the progressive development of obesity,the IR was gradually enhanced (all P < 0.05). Conclusions Hyperinsulinemia and IR may occurred in patients with NAFLD. Moreover,Obesity can aggravate IR and induce secondary glycometabolic disorder.